Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?

Mehta, Rohtesh S.; Saliba, Rima M.; Hayase, Eiko; Jenq, Robert R.; Abraham, Susan C.; Rashid, Asif; Rondón, Gabriela; Alatrash, Gheath; Bashir, Qaiser; Hosing, Chitra; Kebriaei, Partow; Khouri, Issa F.; Marin, David; Nieto, Yago; Olson, Amanda; Oran, Betül; Popat, Uday; Qazilbash, Muzaffar H.; Ramdial, Jeremy; Srour, Samer A.; Champlin, Richard E.; Rezvani, Katayoun; Shpall, Elizabeth J.; Alousi, Amin M.

doi:10.1016/j.jtct.2022.05.039

Cited by 7 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Mehta et al. compared a group treated with PTCy + Tac with a group that received PTCy + Tac + MMF in the context of HLA-matched allo-HCT ( 102 ). The three drug group did not exhibit a lower relapse rate than the two-drug group, but did demonstrate a significantly greater risk of grade II-IV acute GVHD, as well as prolonged neutrophil engraftment by 2 days and an increased risk of bacterial infection.…”

Section: Do the Drugs Administered In Combination With Ptcy Impact Th...mentioning

confidence: 99%

Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation

Nakamae

2024

Front. Immunol.

View full text Add to dashboard Cite

Post-transplant cyclophosphamide (PTCy) is becoming the standard prophylaxis for graft-versus-host disease (GVHD) in HLA-haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) and in HLA-matched allo-HCT. Immune reconstitution in the post-transplant setting may influence the graft-versus-tumor (GVT) effect because PTCy has a profound effect on T cell and natural killer cell functions and their reconstitution after allo-HCT. However, many recent studies have shown that the incidence of relapse after allo-HCT with PTCy is comparable to that after conventional allo-HCT. To further improve the outcomes, it is critical to establish a strategy to maintain or effectively induce the GVT effect when using PTCy as a platform for GVHD prophylaxis. However, there is a paucity of studies focusing on the GVT effect in allo-HCT with PTCy. Therefore, focusing on this issue may lead to the establishment of more appropriate strategies to improve transplantation outcomes without exacerbating GVHD, including novel therapies involving cell modification.

show abstract

Section: Do the Drugs Administered In Combination With Ptcy Impact Th...mentioning

confidence: 99%